1 **Type of issue (IPO/ FPO)** IPO

2 **Issue size (Rs crore)** 631.91

Source: Final post-issue monitoring report dated December 31, 2015

3 **Grade of issue alongwith name of the rating agency** NA / NA

4 **Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged.** 23.63x *

**Net of cheque returns, withdrawals and technical / multiple rejections*

Source: Final post-issue monitoring report dated December 31, 2015

5 **QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges**

(i) allotment in the issue	*2.81%*	*
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2015)	*10.14%*	**
(iii) at the end of 1st FY (31 March 2016)	*12.28%*	**
(iv) at the end of 2nd FY (31 March 2017)	*16.42%*	**
(v) at the end of 3rd FY (31 March 2018)	*24.96%*	**

** As a % of total outstanding share capital post-Issue; Source- minutes of basis of allotment dated December 31, 2015*
*** QIB holding is sum of holding under "institutions" category in Clause 35 filing.*

6 **Financials of the issuer**

(Rs. in crores)

Parameters	*1st FY (FY 2016)*	*2nd FY (FY 2017)*	*3rd FY (FY2018)*
Income from operations	791.32	912.38	1,055.50
Net Profit for the period	133.23	155.19	168.00
Paid-up equity share capital	82.68	83.07	83.30
Reserves excluding revaluation reserves	423.94	576.73	707.80

7 **Trading status in the scrip of the issuer**

(i) at the end of 1st FY 2016	*Frequently Traded*
(ii) at the end of 2nd FY 2017	*Frequently Traded*
(iii) at the end of 3rd FY 2018	*Frequently Traded*

8 **Change, if any, in directors of issuer from the disclosures in the offer document**
(i) at the end of 1st FY (During FY16)

Names of directors	**Details of Change**
Arun Duggal	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*
Anoop Mahendra Singh	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*
Sunil Verma	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*
Saurabh Srivastava	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*

Harneet Singh Chandhoke	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*
Om Prakash Manchanda	*Appointed as Additional (Independent) Director w.e.f. August 21, 2015*
Rahul Sharma	*Liable to retire by rotation at ensuing AGM pursuant to provsions of Companies Act, 2013*

(ii) at the end of 2nd FY (During FY17)

Names of directors	**Details of Change**
Sandeep Singhal	*Resigned (Nominee director) with immediate effect i.e Oct 7, 2016*
Naveen Wadhera	*Resigned (Nominee director) with immediate effect i.e Nov 30, 2016*
Dr. Murugan Rajaram Pandian	*Resigned (Independent director) with immediate effect i.e Feb 14, 2017*

(iii) at the end of 3rd FY (During FY18)

Names of directors	**Details of Change**
None	*NA*

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document
(ii) Actual utilization
(iii) Reasons for deviation, if any

Not Applicable as it was a secondary issue with no money being raised by the Company

11 Comments of monitoring agency, if applicable

(a) Comments on use of funds	*NA*
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	*NA*
(c) Any other reservations expressed by the monitoring agency about the end use of funds	*NA*

12 Price- related data

Issue price (Rs):550 (Rs. 15 discount to the Offer Price was offered to the Retail Individual Bidders)

Price parameters	*At close of*	*At close of*	*At close of*	*As at the end of 1st FY after the listing of the issue*	*As at the end of 2nd FY after the listing of the*	*As at the end of 3rd FY after the listing of*

	listing day (23 Dec 2015)	*30th calendar day from listing day (21 Jan 2016)*	*90th calendar day from listing day (21 March 2016)*	*Closing price (31 Mar 2016)*	*High* [1] *(during the 31 Mar 2016)*	*Low* [2] *(during the 31 Mar 2016)*	*Closing price (31 Mar 2017)*	*High (during the FY 2017)*	*Low (during the FY 2017)*	*Closing price (31 Mar 2018)*	*High (during the FY 2018)*	*Low (during the FY 2018)*
Market Price [3]	825.0	729.0	918.3	923.3	966.9	696.5	967.55	1,246.40	817.50	876.30	976.30	737.35
Index (CNX NIFTY) [4]	7,866.0	7,276.8	7,704.3	7,738.4	7,034.2	6,825.8	9,173.75	9,173.75	7,546.45	10,113.70	11,130.40	9,103.50

(1) High Price is the maximum of the high prices during the said period

(2) Low Price is the minimum of the low prices during the said period

(3) As of NSE (Designated Stock Exchange)

(4) The Company is not part of any Sectoral Index

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	*As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009)* [(1)]		*At the end of 1st FY* [(3)]		*At the end of 2nd FY* [(4)]		*At the end of 3rd FY* [(5)]	
		Audited Restated Unconsolidated Financials- Mar 31, 2015	*Audited Restated Consolidated Financial Statements - Mar 31, 2015*	*Audited Unconsolidated Financials- Mar 31, 2016*	*Audited Consolidated Financial Statements - Mar 31, 2016*	*Audited Unconsolidated Financials- Mar 31, 2017*	*Audited Consolidated Financial Statements - Mar 31, 2017*	*Audited Unconsolidated Financials- Mar 31, 2018*	*Audited Consolidated Financial Statements - Mar 31, 2018*
EPS (based on diluted EPS)	Issuer:	10.71	11.48	15.2	15.98	17.71	18.55	20.48	20.82
	Peer Group:	NA	NA	NA	NA	NA	NA	NA	NA
	Industry Avg:	NA	NA	NA	NA	NA	NA	NA	NA
P/E	Issuer: [(2)]	57.6x	53.4x	77.5x	73.7x	54.6x	51.8x	42.79	42.09
	Peer Group:	NA	NA	NA	NA	NA	NA	NA	NA
	Industry Avg:	NA	NA	NA	NA	NA	NA	NA	NA
RoNW	Issuer:	27.56%	27.85%	26.28%	26.30%	26.0%	23.6%	21.5%	21.7%
	Peer Group:	NA	NA	NA	NA	NA	NA	NA	NA
	Industry Avg:	NA	NA	NA	NA	NA	NA	NA	NA
NAV per share based on balance sheet	Issuer:	53.56	57.56	57.88	61.28	75.24	79.43	93.11	94.97
	Peer Group:	NA	NA	NA	NA	NA	NA	NA	NA
	Industry Avg:	NA	NA	NA	NA	NA	NA	NA	NA

Note: The company is a provider of diagnostic and related healthcare tests and services in India.There are no other relevant listed peers in India which the Dr. Lal PathLabs Limited can be compared with.
(1) Sourced from the Prospectus dated Dec 16, 2015.
(2) P/E based on weighted average Diluted EPS at the floor price.
(3) Sourced from Annual Report, ending Mar 31, 2016 and BSE
(4) Sourced from Company filings for year ended Mar 31, 2017
(5) Sourced from Company filings for year ended Mar 31, 2018

14 Any other material information

1 **29 Mar 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company on March 29, 2016 approved allotment of 32,240 equity shares under the ESOP 2010 Plan of the Company.

2 **1 Apr 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company on April 01, 2016 approved allotment of 66,000 equity shares under the ESOP 2010 Plan of the Company.

3 **13 May 2016:** Dr. Lal PathLabs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 27, 2016, inter alia, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2016 and to consider recommending dividend, if any, on Equity Shares of the Company for the year ended March 31, 2016.
Further, the Trading Window, as per the provisions of the SEBI (Prohibition of insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, will be closed from May 13, 2016 till May 29, 2016 for the purpose of announcement / declaration of such results by the Company.

4 **May 27, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2016 approved shifting of the Registered Office of the Company from 54, Hanuman Road, New Delhi - 110001 to "E-2 Block, Sector 18, Rohini, New Delhi 110089" w.e.f. May 27, 2016.

5 **July 29, 2016:** Dr. Lal PathLabs Ltd has informed BSE that at the meeting of the Nomination & Remuneration Committee ("Committee") held on July 29, 2016 the Committee has granted 2,07,000 (Two Lac Seven Thousand Only) Restricted Stock Unit options ("Options") under the Dr. Lai PathLabs Employee Restricted Stock Unit Plan 2016 ("RSU 2016"/ "Plan") to its employees. The Plan is in terms of SEBI (SBEB) Regulations, 2014, as amended from time to time.

6 **July 29, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company on July 29, 2016 approved allotment of 34,000 equity shares under the ESOP 2010 Plan of the Company.

7 **September 21, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Nomination & Remuneration Committee ("Committee") vide their resolution dated September 21, 2016 granted 8,000 (Eight Thousand Only) Stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2016.

8 **October 07, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Company has, on October 07, 2016 received, an intimation dated October 06, 2016 from Mr. Sandeep Singhal, Nominee Director, tendering his resignation from the Company with immediate effect.

9 **October 08, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company on October 07, 2016 approved allotment of 4,187 equity shares under the ESOP 2010 Plan of the Company.

10 **October 10, 2016:** Dr. Lal PathLabs Ltd has informed BSE that the Nomination & Remuneration Committee ("Committee") vide their resolution dated October 10, 2016 granted 10,000 (Ten Thousand Only) Stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2016 ("RSU 2016"/ "Plan").

11 **October 11, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

12 **October 14, 2016:** Dr. Lal PathLabs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016

13 **October 28, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding Intimation of Conference Call for Investors/ Analyst for Q2 & H1 FY 17.

14 **November 2, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings".

15 **November 3, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding about Result presentation and result press release, standalone and cosnolidated financial results for period ended Sept 30, 2016 and standalone and consolidated limited review for period ended Sept 30, 2016.

16 **November 3, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings".

17 **November 16, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Financial Results Conference Call Transcript of the Company for Q2 H1 FY17"

18 **November 18, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Intimation of Schedule of Analyst / Institutional Investor Meetings".

19 **November 19, 2016:** Dr. Lal PathLabs Ltd has submitted to BSE a Copy of the Notice of Postal Ballot.

20 **November 21, 2016:** With reference to the earlier letter dated May 27, 2016 where in the Company had informed about the Board's decision to acquire 100% stake in M/s. Delta Ria & Pathology Private Limited & to complete the said acquisition within 6 months.In this respect, Dr. Lal PathLabs Ltd has now informed BSE that the Company is in the process of completing the due diligence and legal documentation for the said acquisition, post which it expects to complete the acquisition by March 31, 2017.

21 **November 22, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Intimation of Schedule of Analyst/ Institutional Investor Meetings".

22 **December 21, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding the details of Voting results of Postal Ballot of the Company held on December 21, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report.

23 **December 26, 2016:** Dr. Lal PathLabs Ltd has informed BSE regarding "Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015".

24 **December 31, 2016:** Dr. Lal PathLabs Ltd has informed BSE that a meeting of the Board of Directors is scheduled to be held on February 02, 2017 to inter-alia consider and approve the un-audited financial results of the Company for the Quarter ended December 31, 2016 and to consider the proposal of payment on interim dividend, if any, for the financial Year 2016-17.

25 **January 11, 2017:** Dr. Lal PathLabs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

26 **January 12, 2017:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company on January 11, 2017 approved allotment of 2,85,000 equity shares under the ESOP 2010 Plan of the Company.

27 **January 19, 2017:** Dr. Lal PathLabs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016

28 **January 24, 2017:** The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Pvt ltd

29 **February 2, 2017:** Dr. Lal PathLabs Ltd has informed BSE that the Company has fixed February 14, 2017 as the Record Date for the purpose of Payment of Interim Dividend. The Interim Dividend will be paid by the Company on or after February 21, 2017. Dr. Lal PathLabs Ltd has informed BSE regarding about Result presentation and result press release, standalone and cosnolidated financial results for period ended Dec 31, 2016 and standalone and consolidated limited review for period ended Dec 31, 2016.Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 02, 2017, inter alia, have declared an interim dividend of Rs. 1.30 per equity share (@ 13 % on a face value of Rs. 10/- per share) for the Financial Year 2016-17.

30 **February 2, 2017:** Dr.Lal PathLabs Ltd has informed BSE about Corporate and result Presentation and result release for the period ended December 31, 2016.

31 **February 3, 2017:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors in their meeting held on February 02, 2017 have recommended the appointment of M/s. Deloitte Haskins & Sells LLP as Statutory Auditors of the Company, for a period of five years, in place of the existing auditors M/s. S.R. Batliboi & Co., Chartered Accountants, in compliance with the mandatory

32 **February 27, 2017:** Dr. Lal PathLabs Ltd has informed BSE regarding "Change of Registered Office of Registrar and Share Transfer Agent". Dr. Lal PathLabs Ltd has submitted to BSE a copy of Financial Results Conference Call Transcript of the Company for Q3 9M FY17.

33 **March 03, 2017:** The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanjeevini Investment Holdings.The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for WestBridge Crossover Fund LLC

34 **March 31, 2017:** Dr. Lal PathLabs Ltd has informed BSE that Board of Directors meeting is scheduled on May 12, 2017

35 **April 12, 2017:** Compliance certificate under regulation 40(9) for year ended March 31, 2017has been received by BSE

36 **May 12, 2017**: Dr Lal Path Labs informed the exchange that In compliance with Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (LODR Regulations), we wish to inform you that the Board of Directors in their meeting held today, i.e. May 12, 2017 , approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited (' the

37 **May 12 , 2017:** Dr Lal Path Labs Limited has informed Board of Directors in their meeting heldon May 12, 2017 approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2017.

38 **May 12 , 2017:** Dr. Lal PathLabs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2017, inter alia, has recommended a dividend of Rs. 1.70/- per equity share (@ 17 % on a face value of Rs. 10/- per share) for the year ended March 31, 2017. The dividend, if approved by the shareholders at the ensuing Annual General Meeting (AGM) will be paid on or after July 31, 2017.

39 **May 13, 2017:** Dr. Lal PathLabs Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 14, 2017 to July 20, 2017 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on July 20, 2017

40 **May 17, 2017:** Dr Lal Path labs informed that the Board of Directors of the Company on May 17, 2017 approved allotment of 2,66,560 equity shares under the ESOP 2010 Plan of the Company. You are requested to take note of the above.

41 **Aug 08, 2017:** Please take note that the Board of Directors of the Company, at their meeting held on Monday, August 07, 2017, approved, acquisition of a Company in Bangladesh.

42 **Aug 08, 2017:** Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the meeting of the Nomination & Remuneration Committee ('Committee') held on Monday, August 07, 2017 the Committee has granted 2,15,716 (Two Lac Fifteen Thousand Seven Hundred Sixteen Only) Restricted Stock Unit options ('Options') under the Dr. Lal PathLabs Employee Restricted Stock Unit

43 **Nov 09, 2017:** Please take note that the Board of Directors in their meeting held today i.e. November 9, 2017 approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2017. At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 1.50 per equity share (@ 15 % on a face value of Rs. 10/- per share) for the Financial Year 2017-18

44 **Nov 29, 2017:** Please find enclosed herewith the draft Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company with effect from April 1, 2017 ('Appointed Date') for your information

45 **Dec 12, 2017:** Please take note that the Board of Directors of the Company's Subsidiary Paliwal Diagnostics Private Limited, at their meeting held on Tuesday, December 12, 2017, approved, acquisition of a Proprietorship Concern. i.e. 'Satya Pathology and Diagnostic Centre'.

46 **Dec 29, 2017:** This is to inform you that the Hon'ble New Delhi Bench of the National Company Law Tribunal ('Hon'ble Tribunal' or 'NCLT') by an order dated December 14, 2017 directed convening the meetings of Equity Shareholders and Unsecured Creditors of the Company on Saturday, February 10, 2018 at PHD Chambers of Commerce, No. 4/2 Siri Institutional Area, August Kranti Marg, New Delhi-110016, for approving the Scheme of Amalgamation between Dr. Lal PathLabs Limited (Transferee Company) & Delta Ria and Pathology Private Limtited (Transferor Company).

47 **Dec 29, 2017:** This is to inform you that a meeting of the Board of Directors is scheduled to be held on Thursday, February 08, 2018 to inter-alia consider and approve the un-audited Financial Results of the Company for the Quarter ended December 31, 2017

48 **Feb 12, 2018:** Please take note that the Board of Directors in their meeting held today i.e. February 08, 2018 approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended December 31, 2017

49 **Feb 12, 2018:** Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the meeting of the Nomination & Remuneration Committee ('Committee') held on Thursday, February 08, 2018 the Committee has granted 11,000 (Eleven Thousand) Restricted Stock Unit options ('Options') under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2016 ('RSU 2016'/ 'Plan') to its employees.

50 **Feb 12, 2018:** Dr. Lal PathLabs Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015.

51 **March 30, 2018:** This is to inform you that a meeting of the Board of Directors is scheduled to be held on Monday, May 14, 2018 to inter-alia consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2018 and to consider recommending Final Dividend, if any, on Equity Shares of the Company for the Financial Year ended March 31, 2018

52 **March 30, 2018:** TDr. Lal PathLabs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 14, 2018, inter alia, to consider and approve the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2018, and to consider recommending Final Dividend, if any, on Equity Shares of the Company for the Financial Year ended March 31, 2018

53 **May 14, 2018:** Please take note that the Board of Directors in their meeting held today i.e. May 14, 2018 approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31, 2018. At the said meeting, the Board of Directors have also recommended a dividend of Rs. 3/- per equity share (@ 30 % on a face value of Rs. 10/- per share) for the year ended March 31, 2018.

54 **May 14, 2018:** We wish to inform you that the Board of Directors of the Company on May 14, 2018 approved allotment of 8,866 equity shares under the ESOP 2010 Plan of the Company

55 **July 10, 2018:** Please take note that Mr. Dilip Bidani, Chief Financial Officer has, today i.e July 10, 2018, tendered his resignation from the services of the Company.
Mr. Bidani shall now be serving his notice period in the Company.

56 **Aug 10, 2018:** Please take note that the Board of Directors in their meeting held today i.e. August 10, 2018 approved Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended June 30, 2018.

57 **Aug 10, 2018:** Please take note that the Audit Committee and Board of Directors in their respective meeting held today, approved appointment of Mr. Ved Prakash Goel, as Chief Financial officer and Key Managerial Personnel of the Company w.e.f August 10, 2018

58 **Oct 26, 2018:** We wish to inform you that Hon'ble National Company Law Tribunal ('NCLT'), New Delhi Bench-III has sanctioned the Scheme of Amalgamation between Dr. Lal PathLabs Limited ('The transferee Company') and Delta Ria and Pathology Private Limited ('The transferor Company'), a wholly owned subsidiary of the transferee Company. The said sanction, however, is subject to the approval of scheme by NCLT, Ahmedabad also

59 **Nov 6, 2018:** The Board of Directors in their meeting held today i.e. November 6, 2018 declared an interim dividend of Rs. 2.50 per equity share (@ 25 % on a face value of Rs. 10/- per share) for the Financial Year 2018-19. Dr. Lal PathLabs Ltd has informed BSE that the Company has fixed November 20, 2018 as the Record Date for the purpose of Payment of Interim Dividend.The Interim Dividend will be paid by the Company on or after November 30, 2018.

60 **Nov 6, 2018:** Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), please find attached herewith Corporate Presentation of the Company for Q2 H1 FY19.The aforesaid presentation will also be available on the Company's website- www.lalpathlabs.co

All the above information is updated till Nov 14, 2018, unless indicated otherwise

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the "Circular") for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as "www.capitalmarkets.com" and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of Nov 14, 2018. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.